Who
Kyle Gano
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 208
- Buys
- 0
- Sells
- 56
- Bought
- $0
- Sold
- $54.3M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 4 Sep 2013
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —6,275 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $529K3,386 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —1,842 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $155K994 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —6,275 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $529K3,386 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —1,842 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $155K994 at $156.22 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,241 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,566 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —114,830 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,142 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —2,241 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,241 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,566 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —114,830 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,142 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $150K1,210 at $124.12 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | —2,566 at $0.00 | filing |
| 13 Feb 2026filed 17 Feb 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $172K1,385 at $124.12 | filing |
News
Contrasting Neurocrine Biosciences (NASDAQ:NBIX) and Perrigo (NYSE:PRGO)NBIX · dailypolitical.com · 10 Oct 2026
0 headlines in the last 90 days name Kyle Gano; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.